

Nepal

Support for Vaccine: Measles Rubella This Decision Letter sets out the Programme Terms of a Programme.

1. Country:	Nepal						
2. Vaccine grant number:	15-NPL-08d-Y, 1516-NPL-09a-X, 17-NPL-09a-X, 1819-NPL-09a-X, 20-NPL-09a-X						
3. Date of Decision Letter:	30 September 2019						
4. Date of the Partnership Framework Agreement:	8/22/2014						
5. Programme title:	New Vaccine Support (NVS), Measles Rubella, SD Routine - Strat 1						
6. Vaccine type:	Measles Rubella						
7. Requested product presentation and formulation of vaccine:	Measles Rubella, 10 dose(s) per vial, LYOPHILISED						
8. Programme Duration:¹	2015-2020						
9. Programme Budget (indicative):²	(subject to the terms of the Partnership Framework Agreement, if applicable)						
	2015-2019	2020	2021	2022	2023	2024	Total ²
Programme Budget (US\$)	1,037,702	194,500	-	-	-	-	1,232,202
10. Vaccine introduction grant							
	Approval						
	Year	Grant Number					Amount (US\$)
	2015	15-NPL-08d-Y					546,500
	Disbursement						
	Disbursement date						Amount (US\$)
	28 May, 2015						546,500
11. Product switch grant	Not applicable						
12. Indicative Annual Amounts:³	(subject to the terms of the Partnership Framework Agreement, if applicable)						
Type of supplies to be purchased with Gavi funds	2015-2019	2020					2021
Number of vaccine doses		656,000					-
Annual Amounts (US\$)	1,037,702	194,500					-

¹ This is the entire duration of the programme.

² This is the total amount endorsed by Gavi for the entire duration of the programme.

³ This is the amount that Gavi has approved.

13. Procurement agency:	UNICEF. The Country shall release its co-financing payments each year to UNICEF.	
14. Self-procurement:	Not applicable	
15. Co-financing obligations:	According to the co-financing policy, Country falls within the group Initial self-financing. Please refer to the line 19 below.	
16. Operational support for campaigns:	Not applicable	
17. Additional Reporting Requirements:		
		Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information each year:		
<ul style="list-style-type: none"> • vaccine stock levels including buffer stock, by end of March; • number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. • Countries shall report the actual switch date in the first renewal request following the actual implementation. 		31 March 2020 15 May 2020
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.		To be agreed with Gavi Secretariat
18. Financial clarifications:	Country shall provide the following clarifications to Gavi*: Not applicable * Failure to provide the financial clarifications requested may result in Gavi withholding further disbursements.	

19. Other conditions:

Country has presented an official request to Gavi to switch from measles vaccine to measles-rubella vaccine for the routine measles second dose with country funding for the equivalent cost of the rubella component. As such, country will make the required payments to UNICEF SD as indicated in the table below.

	2020
Number of doses of vaccines for Measles Second Dose approved by Gavi.	656,000
Amount for vaccines approved by Gavi in US\$ (excluding freight and insurance).	188,272
Number of doses of Measles-Rubella vaccine that can be purchased with Gavi support.	287,000
Number of doses of Measles-Rubella vaccine to be funded by country.	369,000
Amount for Measles-Rubella vaccines to be funded by country (excluding freight and insurance).	242,064

In the case of procurement through UNICEF, Gavi-funded vaccines will be purchased only after receipt of full payment of the respective amounts due from Country for the number of doses as indicated in this Decision Letter. Country is required to submit a request for a Estimate to UNICEF, with a clear reference to the approval code and approval year. Country will inform Gavi Secretariat when payment of the respective amount due under this Cost Estimate has been fully made to UNICEF.

In the event that

country wishes to revert to measles vaccine, country should inform UNICEF and Gavi immediately in order to agree on an appropriate arrangement.

Signed by,

On behalf of Gavi



Thabani Maphosa
Managing Director, Country Programmes
30 September 2019